![The Lancet Neurology in conversation with artwork](https://is3-ssl.mzstatic.com/image/thumb/Podcasts114/v4/85/3a/c3/853ac316-eda7-ed9c-1485-b25fad065809/mza_10273963765176715706.jpg/100x100bb.jpg)
John Collinge on a treatment for CJD
The Lancet Neurology in conversation with
English - March 16, 2022 23:00 - 14 minutes - 10.2 MBLife Sciences Science Education stroke alzheimer's epilepsy sleep cerebral multiple sclerosis Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv